Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.57 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 5/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5437755 | 0.81 | BCHE (0.48) | BCHE | |
| SCHEMBL5444561 | 0.81 | BCHE (0.46) | DNM1BCHEMEN1KMT2A | |
| SCHEMBL31362165 | 0.80 | TSHR (0.69) | POLBTSHRSMN1; SMN2HPGDTRPV1 | |
| SCHEMBL3169688 | 0.80 | TSHR (0.69) | POLBTSHRSMN1; SMN2HPGDTRPV1 | |
| SCHEMBL4325517 | 0.79 | TSHR (0.55) | PLA2G1BPOLBATG4BTSHRSMN1; SMN2 | |
| SCHEMBL18076397 | 0.77 | DNM1 (0.56) | DNM1HPGDBCHEALDH1A1 | |
| SCHEMBL5433210 | 0.76 | OPRK1 (0.51) | TSHRMEN1ALDH1A1KMT2AEPHX2 | |
| SCHEMBL5440995 | 0.75 | BCHE (0.46) | POLBBCHEMEN1KMT2A | |
| SCHEMBL18076414 | 0.74 | KMT2A (0.55) | DNM1TSHRBCHEMEN1KMT2A | |
| SCHEMBL25335496 | 0.74 | PNMT (0.50) | TSHRSMN1; SMN2HPGDTRPV1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS AND PHARMACIA & UPJOHN COMPANY LLC | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, CHAT | PLA2G1B 1673/4885POLB 2547/4885ATG4B 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.